Phase 2
N=29
HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity
Sickle Cell Disease · Beta Thalassemia-Major
Bottom Line
View on ClinicalTrials.gov: NCT02435901 ↗Enrolled (actual)
29
Serious AEs
10.3%
Results posted
Nov 2020
Primary outcome: Primary: Number of Participants With Sustained Cell Engraftment of Donor Cells — 29 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- alemtuzumab (Campath IH) (Drug); Fludarabine (Drug); Melphalan (Drug); Cyclosporine (Drug); Mycophenolate mofetil (Drug); Tacrolimus (Drug); Hematopoietic Stem Cell Transplantation (Biological)
- Age
- Pediatric, Adult · 1+ yrs
- Sex
- All
- Sponsor
- Northwell Health
- Primary completion
- Mar 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Sustained Cell Engraftment of Donor Cells |
29 | — |
| SECONDARY Assessment of Treatment Related Mortality and Morbidity |
13; 9; 7 | — |
| SECONDARY Event Free Survival; Number of Participants Who Survived at 2 Years |
1; 2; 26 | — |
Summary
This study will evaluate the use of reduced intensity conditioning regimen in patients with high risk hemoglobinopathy Sickle Cell and B-Thalassemia Major in combination with standard immunosuppressive medications, followed by a routine stem cell transplant in order to assess whether or not it is as effective as myeloablative high dose chemotherapy and transplant.
Eligibility Criteria
Inclusion Criteria
- Patient Inclusion Criteria for Sickle Cell Disease
- Patients at least one year of age to less than or equal to 21 years of age with (Sickle Cell Disease-SS or Sickle Cell-S-β-Thalassemia and with one or more of the following disease complications:
- Development of stroke on chronic transfusion protocol.
- Allosensitization on chronic transfusion therapy
- Impaired neuropsychological function and abnormal MRI scan
- Abnormal Transcranial Doppler studies
- Acute chest syndrome (2 to 3 episodes of acute chest syndrome in last 3 to 4 years).
- Ferritin level < 1500 mg/ml
- Recurrent painful priapism; 3-4 episodes/year requiring intervention.
- Recurrent vaso-occlusive crisis of at least 3 to 4 episodes/year.
- Osteonecrosis of multiple bones with documented destructive changes.
- Signed informed consent
- Patients physically and psychologically capable of undergoing transplantation and a period of strict isolation.
- Ferritin < 1500
- Liver Iron Concentration < 6mg/g
Patient Inclusion Criteria for β Thalassemia major Patients less than or equal to 21 years of age with B- Thalassemia major on routine monthly transfusion protocol or with one or more of the following complications;
- Hepatomegaly.
- Liver biopsy revealing evidence of portal fibrosis as A) Mild B) Moderate
- Ferritin level≤ 1500ng/ml
- Liver Iron Concentration (LIC) < 6mg/g
Exclusion Criteria
- Exclusion Criteria for Both Sickle Cell and β Thalassemia Major Patient
- HIV positive result confirmed by Western Blot.
- Pregnancy (Pregnancy testing for females of child-bearing age will be performed and those with a positive serum β-Human Chorionic Gonadotropin will be excluded) and lactating females.
- Creatinine greater than two times the upper limit of normal for the laboratory,
- Pulmonary disease with FVC, FEV1 or DLCO parameters < 50% predicted (corrected for hemoglobin) or stage 3 or 4 sickle lung disease.
- Cardiac insufficiency or coronary artery disease requiring treatment
- Active infection requiring systemic antibiotic therapy with antibacterial, antifungal or antiviral agents
- Lansky performance score <70%- (Appendix B)
- Acute hepatitis/biopsy evidence of cirrhosis.
- Pulmonary Hypertension
Data sourced from ClinicalTrials.gov (NCT02435901). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.